secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001213900-24-020882
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics FY2023 net loss from operations down 50% to $17.1M; stenoparib complete response in Phase 2
--------------------------------------------------------------------------------

- Net loss from operations $17.1M in 2023 vs $34M in 2022 (down 50%); net loss $11.9M vs $16.1M.
- R&D expenses $7.1M and G&A $10.0M both flat year-over-year; no product revenue reported.
- Interim CEO Thomas Jensen appointed Dec 2023; former Eli Lilly exec Jeremy Graff named Executive Advisor.
- Dec 2023 Phase 2 stenoparib data: 1 complete response, 4 stable disease in evaluable advanced ovarian cancer patients.
- Expects interim Phase 2 stenoparib data in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/0001213900-24-020882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/ea0201409-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-020882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer